Advanced search
Publication Cover
Biomarkers Volume 17, 2012 - Issue 8
Submit an article Journal homepage
247
Views
41
CrossRef citations to date
0
Altmetric
Research Article

Galectin 3 complements BNP in risk stratification in acute heart failure

Gregory J. FermannDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USACorrespondence[email protected]
,
Christopher J. LindsellDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA
,
Alan B. StorrowDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA
,
Kimberly HartDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA
,
Matthew SperlingDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA
,
Susan RollDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA
,
Neal L. WeintraubDivision of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
,
Karen F. MillerDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA
,
David J. Maron
,
Allen J. NaftilanDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA
,
John A. McphersonDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA
,
Douglas B. SawyerDivision of Cardiovascular Diseases, Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA
,
Robert ChristensonDepartment of Laboratory Medicine,University of Maryland, Baltimore, MD, USA
&
Sean P. CollinsDepartment of Emergency Medicine, Vanderbilt University, Nashville, TN, USA
 show all
Pages 706-713 | Received 01 Aug 2012, Accepted 03 Aug 2012, Published online: 24 Sep 2012
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Background: Galectin 3 (G3) is a mediator of fibrosis and remodeling in heart failure.

Methods: Patients diagnosed with and treated for Acute Heart Failure Syndromes were prospectively enrolled in the Decision Making in Acute Decompensated Heart Failure multicenter trial.

Results: Patients with a higher G3 had a history of renal disease, a lower heart rate and acute kidney injury. They also tended to have a history of HF and 30-day adverse events compared with B-type natriuretic peptide.

Conclusion: In Acute Heart Failure Syndromes, G3 levels do not provide prognostic value, but when used complementary to B-type natriuretic peptide, G3 is associated with renal dysfunction and may predict 30-day events.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 527.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.